A Multicenter Cancer Biospecimen Collection Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1650 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-05

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

NCT07327489

Skin Cancer Cancer Immunotherapy +12 more

RECRUITING

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ann Arbor Stage I Lymphoma +59 more

RECRUITING

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer

NCT02245100

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Salivary Gland Squamous Cell Carcinoma Stage IIIA Non-small Cell Lung Cancer +27 more

COMPLETED

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

NCT00904514

Cancer

TERMINATED

Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers

NCT01031056

Gastrointestinal Neoplasms Gynecologic Cancers Gynecologic Cancers Cervical Cancer +11 more

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will establish a prospective cohort of pre-treatment tumor specimens with correlated de-identified clinical and demographic data and tissue histology from cancer patients who are undergoing treatment with PD-1/PD-L1 inhibitors. Patients who have undergone pre-anti-PD-1/PD-L1-treatment tumor biopsy or who are scheduled for tumor biopsy prior to anti-PD-1/PD-L1 treatment will be enrolled.

The study will not require a study-specific tumor biopsy; any biopsies taken prior to treatment as part of standard of care are eligible for this study. Biopsies must not have been taken after immunotherapy treatment began.

Participants will be asked to provide their consent for the potential use of their biospecimens in subsequent studies for the development and validation of a diagnostic test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer of Head and Neck Lung Cancer, Nonsmall Cell Small-cell Lung Cancer Urothelial Carcinoma Gastroesophageal Junction Adenocarcinoma Cervical Cancer Esophageal Squamous Cell Carcinoma Triple Negative Breast Cancer Hepatocellular Carcinoma Renal Cell Carcinoma Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.